Zenta Tsuchihashi
Senior Director, Translational Patient Safety, Clinical Safety & Pharmacovigilance Daiichi Sankyo
Zenta Tsuchihashi is Senior Director of Translational Patient Safety at Daiichi Sankyo, where he specializes in the development and safety of ADCs, including ENHERTU®. He leads translational safety strategies that integrate clinical, biomarker, and mechanistic insights to better understand and mitigate ADC-related toxicities, particularly in oncology.
With extensive experience across translational science and oncology drug development, Tsuchihashi focuses on bridging preclinical findings and clinical outcomes to optimize ADC therapies. His work is central to advancing safer, more effective targeted treatments for patients with cancer.
Seminars
Re-join your expert speakers in a closing panel discussion as they explore the best approaches to characterize, predict and mitigate ADC’s largest barrier to widen therapeutic index. Bring your top questions as the speakers discuss best methods to predict ADC clinical safety profiles, optimize patient selection, and mitigate adverse events.
Discussion Highlights Include:
- Understanding transferable learnings and new considerations to assess the safety profile of non-cytotoxic and novel format ADCs
- Breaking down how best to deploy in vivo and in vitro models to improve prediction of ADC clinical
- safety profiles
- Tackling opportunities and strategies to identify high risk patients and mitigate clinical ADC toxicities
- What are the toxicity-led barriers to overcome for ADCs progression to earlier-line patient therapies
